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the “change from baseline” of the IPSS score (p0.1464). The same applies to the
analyses at 3 and 6 months where the p-values were 0.1156 and 0.1723 respectively.
Concerning the 2 dimensions of SF12 score, we observe an improvement but there
is no statistical difference between the 2 treatment groups (physical dimension,
p0.6954 and 0.9878 at 6 weeks and 6 months respectively; mental dimension,
p0.5139 and 0.9044 at 6 weeks and 6 months respectively). CONCLUSIONS: We
observed an improvement in the IPSS and SF12 scores from 6 weeks. This improve-
ment was not significantly different between the 2 treatment groups. Under actual
conditions of use, the various medical treatments gave similar improvements.
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OBJECTIVES: Impact studies evaluate the benefit of vaccination on specific out-
come measures in real live conditions. Those studies collect raw data that do not
allow for making general assessments because sometimes the numbers are too
low. Modelling techniques can fine-tune the raw data into more harmonised
( parametric) data presentation. But what do we learn after this transformation?
METHODS: We collected data over 5 years on hospitalisation due to rotavirus in-
fection in children  5 years old before (2y) and after (3y) the introduction of
vaccination in 9 Belgian hospitals. We split the annual data by age-group of 2 to 3
months when  1-year-old and by year thereafter over the period of the epidemic
spread. We harmonised the data using Riskview software in Excel
®
. The hypothe-
ses tested are that the age-groups most vulnerable to the disease have the largest
epidemic spread (highest number of weeks/y of cases reported) and that the less
vulnerable age-groups have their spread during the peak weeks of the most vul-
nerable ones. The latter should indicate a way of disease transmission between
age-groups that could be confirmed with vaccination. RESULTS: Pre-vaccination
data analysis indicates the widest spread of the disease in the age-group of 9 to 11
months (39 wks/52) and the smallest ones in the very young (33 wks/52) and the
oldest ones (8 wks/52). The data confirms the spread of the disease in the less
vulnerable ones (younger and older ones) occurring during the peak moment of the
season of the most vulnerable ones. Post-vaccination analysis shows the same
pattern of dependency between the age-groups. CONCLUSIONS: Preferential
spread of the disease starting from the 9 to 11 months old age-group to younger and
older ones can be deduced from the data analysis. This could give an explanation
for the annual self-limiting spread of rotavirus disease.
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OBJECTIVES: Repeat chlamydial infections are known to cause tubal scarring, ec-
topic pregnancy and infertility. CDC has recommended rescreening 3 months after
a diagnosis of Chlamydia. The objective was to examine the rate and predictors of
retesting within 3-6 months among patients (15-50 years) diagnosed with Chla-
mydia in privately insured population. METHODS: A commercial insurance data-
base was used to extract patients with Chlamydia (ICD-9-CM codes: 99.5X, 78.88,
79.88, 79.98, 99.41) in year 2007-2009. The date of first Chlamydia diagnosis was
used as the index date. Patients were required to have private health insurance
6 months before and after the index date. We also defined the re-screening service
for Chlamydia by using the CPT codes: 87270, 87320, 87110, 87491, 87492, and 87801
within 3-6 months after the index date. Logistic regression model was used to
identify factors affecting the likelihood of Chlamydia retesting. RESULTS: Among
2585 persons diagnosed with Chlamydia, the distribution across age group was
59.8% (15-25 years), 31.2% (26-40 years), and 9.0% (41-50). The majority were women
(74.2%). Only 9.8% (252/2585) patients were rescreened within 3-6 months. The rate
of re-screening in 2007, 2008 and 2009 was 9.1%, 10.3%, and 9.2%, respectively. The
rescreened individuals were more likely to be: women but not pregnant (OR2.36,
95% CI: 1.59-3.50), pregnant women (OR3.01, 95% CI: 1.76-5.13), compared to men;
and age 15-25 years old (OR2.65, 95% CI1.33-5.30), compared to the age group
40-50 years. The insurance type, region or index year were not significantly asso-
ciated with retesting. CONCLUSIONS: Low re-screening rates persisted among per-
sons diagnosed with Chlamydia in the private sector. Since insurance type and
region show no impact on retesting, low rates may relate to system-wide problems.
To improve rescreening rate, policy makers should urgently consider policy op-
tions including rescreening of all Chlamydia cases for effective control of the dis-
ease.
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OBJECTIVES: Herpes zoster (HZ), which is caused by reactivation of the varicella-
zoster-virus (VZV), and its main complication postherpetic neuralgia (PHN) are not
notifiable in Germany. HZ disease burden data are needed to i) estimate the eco-
nomic impact of the disease ii) monitor the impact of routine childhood varicella
vaccination on HZ-epidemiology, and iii) guide decision-making related to the de-
velopment of a possible HZ-vaccination recommendation. METHODS: We as-
sessed annual HZ-incidence for 2007/2008 for all ages in person-years (PY). For
HZ-outpatient incidence we utilized the Association of Statutory Health Insurance
Physicians (ASHIP) database containing nationwide routine accounting data. An-
nual number of HZ-associated deaths and HZ-inpatients were identified by using
the Federal Health Monitoring System (FHM). PHN-incidence and loss of quality-
adjusted life years (QALYs) were modelled by multiplying upper and lower limit
estimates for proportion of HZ-cases developing PHN and HZ-related QALY-loss
with number of identified HZ-outpatients. RESULTS: We identified an annual av-
erage of 480,927 HZ-outpatient cases, resulting in a HZ-incidence of 5.9/1,000 PY. Of
these, 63.5% were 50 years and over. On average, 16,964 HZ-associated inpatients
(84% 50 years) and 71 deaths (all 50 years) were reported annually. HZ-outpa-
tient incidence increased by age from 2.71/1,000 PY in people 0-14 years to 13.18/
1,000 PY in people aged 90. In terms of outpatient (6.94 vs. 4.81/1,000 PY) and
inpatient (0.24 vs. 0.17/1,000 PY) HZ-incidence and mortality (0.13 vs. 0.04/100,000
PY) females were significantly more affected. We estimated that PHN-incidence
ranged between 0.18 and 1.33/1,000 PY and that HZ-outpatients lost between 4,807
and 27,179 QALYs annually.CONCLUSIONS:HZ poses a considerable burden on the
health care system in Germany, especially in the elderly. A health economic model
for Germany will be developed, and follow-up assessments of epidemiological and
economic HZ-related disease burden will be performed to monitor the impact of
VZV-vaccinations in Germany.
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OBJECTIVES: The aging of the Taiwan population is one of the major public health
issues we face now. The physical difference between young and elderly is signifi-
cant and may induce many drug-related problems. Once geriatrics suffered from
adverse drug reactions, they may need for intensive care and increased the finan-
cial burden. Consequently, medication safety is one of the critical issues for elderly.
Analyzing the adverse drug reactions in geriatric patients and announce to health-
care related professionals to prevent the incidences. METHODS: The data was
claimed form Reporting System of Adverse Drug Reaction of a regional teaching
hospital from Jan 2010 to Dec 2010. RESULTS: Four hundred forty cases were ex-
tracted from computer-assisted system. Of 228 geriatrics (51.82%) was enrolled
with mean age 77.03  0.74 years old, including 116 female and 112 male. The
reason to cause adverse drug reaction is Type 1 (58.26 %), undesired pharmacology
reaction, and others were Type 2 (41.74%). The most strategies to management
adverse effects were to cease medicine and give another relievable drug (29.82%),
only cease medicine (28.51%) and varied to alternative medicine (21.93%). Analyz-
ing the severity of event, 55.26% is moderate (needing therapy or inducing to admit
hospital ).CONCLUSIONS:Over half events happened on elderly and make patients
need more advance therapy, and undesired pharmacology effects, which are pre-
ventable, are the most reasons. For this reason, health care related professionals
should pay more attention and monitor closely to enhance medication safety when
a drug was prescribed to elderly.
Individual’s Health – Cost Studies
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OBJECTIVES: To describe the burden of illness associated with neural tube defects
(NTDs) in Germany from a payer perspective. METHODS: Retrospective data of
patients with Spina Bifida (SB) and Encephalocele were analyzed using 2006-2009
German health insurance fund data (Techniker Krankenkasse). Patients were iden-
tified using ICD10 codes, data assessed included outpatient and inpatient care,
rehabilitation, remedies and medical aids, and use of pharmacotherapy. The anal-
ysis was stratified by age group to provide a lifetime burden estimate and was
compared to standardized health care expenditures from the German Risk Com-
pensation Scheme (RSA) to obtain an indicator of incremental burden due to NTD.
RESULTS: Overall, 4,173 patients were identified, 47.2% of whom were male and
95% had SB. 19.6% and 17.5% patients had an additional diagnosis of depression
and incontinence respectively. Costs of patients with SB and Encephalocele were
substantially higher than general population in all age strata. The difference was
highest for patients10 years old (€10,775 vs. €2,360 for1 year olds, €8,398 vs. €833
for 2-5, and €10,686 vs. €863 for 6-10) and smallest for 41-50 (€2,596 vs. €1,101) and
71 group (€5,256 vs. €4,389). Inpatient care contributed 78% of total cost for pa-
tients 0-1, whereas remedies and medical aids accounted for 60% of total cost for
patients 2-5 and 6-10. Among sub-groups, costs of patients with Spina Bifida and
Hydrocephalus were highest, especially in the first 10 years of life. CONCLUSIONS:
The burden of NTD in Germany is substantial and continues throughout the patient
life in terms of the level of health care expenditures and relative to overall popu-
lation. Efforts should be devoted to improving prevention of NTDs and providing
appropriate support for patients, parents, and caregivers, especially in early years.
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BACKGROUND: Seasonal epidemics with rotavirus gastroenteritis (RVGE) and re-
spiratory syncytial virus (RSV) represent a significant burden on paediatric clinical
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